Advertisement

Turning Over a New Leaf—Pharmacologic Therapy in Obstructive Sleep Apnea

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Sleep Medicine Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Benjafield A.V.
        • Ayas N.T.
        • Eastwood P.R.
        • et al.
        Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis.
        Lancet Respir Med. 2019; 7: 687-698
        • Dempsey J.A.
        • Veasey S.C.
        • Morgan B.J.
        • et al.
        Pathophysiology of sleep apnea.
        Physiol Rev. 2010; 90: 47-112
        • McNicholas W.T.
        • Bonsigore M.R.
        • Management Committee of ECAB
        Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities.
        Eur Respir J. 2007; 29: 156-178
        • Javaheri S.
        • Barbe F.
        • Campos-Rodriguez F.
        • et al.
        Sleep apnea: Types, mechanisms, and clinical cardiovascular consequences.
        J Am Coll Cardiol. 2017; 69: 841-858
        • Randerath W.
        • Verbraecken J.
        • de Raaff C.A.L.
        • et al.
        European Respiratory Society guideline on non-CPAP therapies for obstructive sleep apnoea.
        Eur Respir Rev. 2021; 30https://doi.org/10.1183/16000617.0200-2021
        • Hedner J.
        • Zou D.
        Drug therapy in obstructive sleep apnea.
        Sleep Med Clin. 2018; 13: 203-217
        • Gaisl T.
        • Haile S.R.
        • Thiel S.
        • et al.
        Efficacy of pharmacotherapy for OSA in adults: a systematic review and network meta-analysis.
        Sleep Med Rev. 2019; 46: 74-86
        • Mason M.
        • Welsh E.J.
        • Smith I.
        Drug therapy for obstructive sleep apnoea in adults.
        Cochrane Database Syst Rev. 2013; : CD003002https://doi.org/10.1002/14651858.CD003002.pub3
        • Taranto-Montemurro L.
        • Messineo L.
        • Wellman A.
        Targeting endotypic traits with medications for the pharmacological treatment of obstructive sleep apnea. A review of the current literature.
        J Clin Med. 2019; 8https://doi.org/10.3390/jcm8111846
        • Bosi M.
        • Incerti Parenti S.
        • Sanna A.
        • et al.
        Non-continuous positive airway pressure treatment options in obstructive sleep apnoea: a pathophysiological perspective.
        Sleep Med Rev. 2021; 60: 101521https://doi.org/10.1016/j.smrv.2021.101521
        • Weaver T.E.
        • Grunstein R.R.
        Adherence to continuous positive airway pressure therapy: the challenge to effective treatment.
        Proc Am Thorac Soc. 2008; 5: 173-178
        • McEvoy R.D.
        • Antic N.A.
        • Heeley E.
        • et al.
        CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea.
        N Engl J Med. Sep 8 2016; 375: 919-931https://doi.org/10.1056/NEJMoa1606599
        • Grote L.
        • Hedner J.
        • Grunstein R.
        • et al.
        Therapy with nCPAP: incomplete elimination of sleep related breathing disorder.
        Eur Respir J. 2000; 16: 921-927
        • Oh A.
        • Grivell N.
        • Chai-Coetzer C.L.
        What is a clinically Meaningful target for positive airway pressure adherence?.
        Sleep Med Clin. 2021; 16: 1-10
        • Kohler M.
        • Bloch K.E.
        • Stradling J.R.
        Pharmacological approaches to the treatment of obstructive sleep apnoea.
        Expert Opin Investig Drugs. 2009; 18: 647-656
        • Radmand R.
        • Chiang H.
        • Di Giosia M.
        Defining and measuring compliance with oral appliance therapy.
        J Dent Sleep Med. 2021; 8
        • McNicholas W.T.
        • Bassetti C.L.
        • Ferini-Strambi L.
        • et al.
        Challenges in obstructive sleep apnoea.
        Lancet Respir Med. 2018; 6: 170-172
        • Pevernagie D.A.
        • Gnidovec-Strazisar B.
        • Grote L.
        • et al.
        On the rise and fall of the apnea-hypopnea index: a historical review and critical appraisal.
        J Sleep Res. 2020; 29: e13066
        • Malhotra A.
        • Ayappa I.
        • Ayas N.
        • et al.
        Metrics of sleep apnea severity: beyond the apnea-hypopnea index.
        Sleep. 2021; 44https://doi.org/10.1093/sleep/zsab030
        • Kulkas A.
        • Tiihonen P.
        • Eskola K.
        • et al.
        Novel parameters for evaluating severity of sleep disordered breathing and for supporting diagnosis of sleep apnea-hypopnea syndrome.
        J Med Eng Technol. 2013; 37: 135-143
        • Azarbarzin A.
        • Sands S.A.
        • Stone K.L.
        • et al.
        The hypoxic burden of sleep apnoea predicts cardiovascular disease-related mortality: the Osteoporotic Fractures in Men Study and the Sleep Heart Health Study.
        Eur Heart J. 2019; 40: 1149-1157
        • Mazzotti D.R.
        • Keenan B.T.
        • Lim D.C.
        • et al.
        Symptom subtypes of obstructive sleep apnea Predict Incidence of cardiovascular outcomes.
        Am J Respir Crit Care Med. 2019; 200: 493-506
        • Suurna M.V.
        • Jacobowitz O.
        • Chang J.
        • et al.
        Improving outcomes of hypoglossal nerve stimulation therapy: current practice, future directions, and research gaps. Proceedings of the 2019 International Sleep Surgery Society Research Forum.
        J Clin Sleep Med. 2021; 17: 2477-2487
        • Randerath W.
        • Bassetti C.L.
        • Bonsignore M.R.
        • et al.
        Challenges and perspectives in obstructive sleep apnoea: report by an ad hoc working group of the sleep disordered breathing group of the European respiratory Society and the European sleep research Society.
        Eur Respir J. 2018; 52https://doi.org/10.1183/13993003.02616-2017
        • Eckert D.J.
        • White D.P.
        • Jordan A.S.
        • et al.
        Defining phenotypic causes of obstructive sleep apnea. Identification of novel therapeutic targets.
        Am J Respir Crit Care Med. 2013; 188: 996-1004
        • Eckert D.J.
        Phenotypic approaches to obstructive sleep apnoea - new pathways for targeted therapy.
        Sleep Med Rev. 2018; 37: 45-59
        • Winslow D.H.
        • Bowden C.H.
        • DiDonato K.P.
        • et al.
        A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults.
        Sleep. 2012; 35: 1529-1539
        • Taranto-Montemurro L.
        • Messineo L.
        • Sands S.A.
        • et al.
        The combination of atomoxetine and oxybutynin greatly reduces obstructive sleep apnea severity. A randomized, placebo-controlled, double-blind crossover trial.
        Am J Respir Crit Care Med. 2019; 199: 1267-1276
        • Lim R.
        • Messineo L.
        • Grunstein R.R.
        • et al.
        The noradrenergic agent reboxetine plus the antimuscarinic hyoscine butylbromide reduces sleep apnoea severity: a double-blind, placebo-controlled, randomised crossover trial.
        J Physiol. 2021; 599: 4183-4195
        • Perger E.
        • Taranto Montemurro L.
        • Rosa D.
        • et al.
        Reboxetine Plus Oxybutynin for OSA Treatment: A 1-Week, Randomized, Placebo-Controlled, Double-Blind Crossover Trial.
        Chest. Jan 2022; 161: 237-247https://doi.org/10.1016/j.chest.2021.08.080
        • Younes M.
        Role of arousals in the pathogenesis of obstructive sleep apnea.
        Am J Respir Crit Care Med. 2004; 169: 623-633
        • Eckert D.J.
        • Owens R.L.
        • Kehlmann G.B.
        • et al.
        Eszopiclone increases the respiratory arousal threshold and lowers the apnoea/hypopnoea index in obstructive sleep apnoea patients with a low arousal threshold.
        Clin Sci (Lond). 2011; 120: 505-514
        • Eckert D.J.
        • Malhotra A.
        • Wellman A.
        • et al.
        Trazodone increases the respiratory arousal threshold in patients with obstructive sleep apnea and a low arousal threshold.
        Sleep. 2014; 37: 811-819
        • Carter S.G.
        • Berger M.S.
        • Carberry J.C.
        • et al.
        Zopiclone increases the arousal threshold without impairing genioglossus activity in obstructive sleep apnea.
        Sleep. 2016; 39: 757-766
        • Carberry J.C.
        • Fisher L.P.
        • Grunstein R.R.
        • et al.
        Role of common hypnotics on the phenotypic causes of obstructive sleep apnoea: paradoxical effects of zolpidem.
        Eur Respir J. 2017; 50https://doi.org/10.1183/13993003.01344-2017
        • Younes M.
        • Ostrowski M.
        • Thompson W.
        • et al.
        Chemical control stability in patients with obstructive sleep apnea.
        Am J Respir Crit Care Med. 2001; 163: 1181-1190
        • Schmickl C.N.
        • Landry S.A.
        • Orr J.E.
        • et al.
        Acetazolamide for OSA and central sleep apnea: a Comprehensive systematic review and meta-analysis.
        Chest. 2020; 158: 2632-2645
        • Brownell L.G.
        • West P.
        • Sweatman P.
        • et al.
        Protriptyline in obstructive sleep apnea: a double-blind trial.
        N Engl J Med. 1982; 307: 1037-1042
        • Smith P.L.
        • Haponik E.F.
        • Allen R.P.
        • et al.
        The effects of protriptyline in sleep-disordered breathing.
        Am Rev Respir Dis. 1983; 127: 8-13
        • Whyte K.F.
        • Gould G.A.
        • Airlie M.A.
        • et al.
        Role of protriptyline and acetazolamide in the sleep apnea/hypopnea syndrome.
        Sleep. 1988; 11: 463-472
        • Bart Sangal R.
        • Sangal J.M.
        • Thorp K.
        Atomoxetine improves sleepiness and global severity of illness but not the respiratory disturbance index in mild to moderate obstructive sleep apnea with sleepiness.
        Sleep Med. 2008; 9: 506-510
        • Taranto-Montemurro L.
        • Messineo L.
        • Azarbarzin A.
        • et al.
        Effects of the combination of atomoxetine and oxybutynin on OSA endotypic traits.
        Chest. 2020; 157: 1626-1636
        • Osanai S.
        • Akiba Y.
        • Fujiuchi S.
        • et al.
        Depression of peripheral chemosensitivity by a dopaminergic mechanism in patients with obstructive sleep apnoea syndrome.
        Eur Respir J. 1999; 13: 418-423
        • Larrain A.
        • Kapur V.K.
        • Gooley T.A.
        • et al.
        Pharmacological treatment of obstructive sleep apnea with a combination of pseudoephedrine and domperidone.
        J Clin Sleep Med. 2010; 6: 117-123
        • Liu X.
        • Sood S.
        • Liu H.
        • et al.
        Opposing muscarinic and nicotinic modulation of hypoglossal motor output to genioglossus muscle in rats in vivo.
        J Physiol. 2005; 565: 965-980
        • Gothe B.
        • Strohl K.P.
        • Levin S.
        • et al.
        Nicotine: a different approach to treatment of obstructive sleep apnea.
        Chest. 1985; 87: 11-17
        • Davila D.G.
        • Hurt R.D.
        • Offord K.P.
        • et al.
        Acute effects of transdermal nicotine on sleep architecture, snoring, and sleep-disordered breathing in nonsmokers.
        Am J Respir Crit Care Med. 1994; 150: 469-474
        • Zevin S.
        • Swed E.
        • Cahan C.
        Clinical effects of locally delivered nicotine in obstructive sleep apnea syndrome.
        Am J Ther. 2003; 10: 170-175
        • Slamowitz D.I.
        • Edwards J.K.
        • Chajek-Shaul T.
        • et al.
        The influence of a transmucosal cholinergic agonist on pharyngeal muscle activity.
        Sleep. 2000; 23: 543-550
        • Gilman S.
        • Chervin R.D.
        • Koeppe R.A.
        • et al.
        Obstructive sleep apnea is related to a thalamic cholinergic deficit in MSA.
        Neurology. 2003; 61: 35-39
        • Hedner J.
        • Kraiczi H.
        • Peker Y.
        • et al.
        Reduction of sleep-disordered breathing after physostigmine.
        Am J Respir Crit Care Med. 2003; 168: 1246-1251
        • Sukys-Claudino L.
        • Moraes W.
        • Guilleminault C.
        • et al.
        Beneficial effect of donepezil on obstructive sleep apnea: a double-blind, placebo-controlled clinical trial.
        Sleep Med. 2012; 13: 290-296
        • Li Y.
        • Owens R.L.
        • Sands S.
        • et al.
        The effect of donepezil on arousal threshold and apnea-hypopnea index. A randomized, double-blind, Cross-over study.
        Ann Am Thorac Soc. 2016; 13: 2012-2018
        • Lipford M.C.
        • Ramar K.
        • Liang Y.J.
        • et al.
        Serotnin as a possible biomarker in obstructive sleep apnea.
        Sleep Med Rev. 2016; 28: 125-132
        • Real C.
        • Seif I.
        • Adrien J.
        • et al.
        Ondansetron and fluoxetine reduce sleep apnea in mice lacking monoamine oxidase A.
        Respir Physiol Neurobiol. 2009; 168: 230-238
        • Neuzeret P.C.
        • Sakai K.
        • Gormand F.
        • et al.
        Application of histamine or serotonin to the hypoglossal nucleus increases genioglossus muscle activity across the wake-sleep cycle.
        J Sleep Res. 2009; 18: 113-121
        • Kraiczi H.
        • Hedner J.
        • Dahlof P.
        • et al.
        Effect of serotonin uptake inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea.
        Sleep. 1999; 22: 61-67
        • Maierean A.D.
        • Bordea I.R.
        • Salagean T.
        • et al.
        Polymorphism of the serotonin transporter gene and the peripheral 5-hydroxytryptamine in obstructive sleep apnea: what do We Know and what are We looking for? A systematic review of the literature.
        Nat Sci Sleep. 2021; 13: 125-139
        • Veasey S.C.
        Serotonin agonists and antagonists in obstructive sleep apnea: therapeutic potential.
        Am J Respir Med. 2003; 2: 21-29
        • Veasey S.C.
        • Chachkes J.
        • Fenik P.
        • et al.
        The effects of ondansetron on sleep-disordered breathing in the English bulldog.
        Sleep. 2001; 24: 155-160
        • Stradling J.
        • Smith D.
        • Radulovacki M.
        • et al.
        Effect of ondansetron on moderate obstructive sleep apnoea, a single night, placebo-controlled trial.
        J Sleep Res. 2003; 12: 169-170
        • Sood S.
        • Morrison J.L.
        • Liu H.
        • et al.
        Role of endogenous serotonin in modulating genioglossus muscle activity in awake and sleeping rats.
        Am J Respir Crit Care Med. 2005; 172: 1338-1347
        • Hanzel D.A.
        • Proia N.G.
        • Hudgel D.W.
        Response of obstructive sleep apnea to fluoxetine and protriptyline.
        Chest. 1991; 100: 416-421
        • Sunderram J.
        • Parisi R.A.
        • Strobel R.J.
        Serotonergic stimulation of the genioglossus and the response to nasal continuous positive airway pressure.
        Am J Respir Crit Care Med. 2000; 162: 925-929
        • Berry R.B.
        • Yamaura E.M.
        • Gill K.
        • et al.
        Acute effects of paroxetine on genioglossus activity in obstructive sleep apnea.
        Sleep. 1999; 22: 1087-1092
        • Aslan S.
        • Isik E.
        • Cosar B.
        The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers.
        Sleep. 2002; 25: 677-679
        • Berry R.B.
        • Koch G.L.
        • Hayward L.F.
        Low-dose mirtazapine increases genioglossus activity in the anesthetized rat.
        Sleep. 2005; 28: 78-84
        • Carley D.W.
        • Radulovacki M.
        Mirtazapine, a mixed-profile serotonin agonist/antagonist, suppresses sleep apnea in the rat.
        Am J Respir Crit Care Med. 1999; 160: 1824-1829
        • Carley D.W.
        • Olopade C.
        • Ruigt G.S.
        • et al.
        Efficacy of mirtazapine in obstructive sleep apnea syndrome.
        Sleep Jan. 2007; 30: 35-41
        • Marshall N.S.
        • Yee B.J.
        • Desai A.V.
        • et al.
        Two randomized placebo-controlled trials to evaluate the efficacy and tolerability of mirtazapine for the treatment of obstructive sleep apnea.
        Sleep. 2008; 31: 824-831
        • Wang T.
        • Eskandari D.
        • Zou D.
        • et al.
        Increased carbonic anhydrase activity is associated with sleep apnea severity and related hypoxemia.
        Sleep. 2015; 38: 1067-1073
        • Edwards B.A.
        • Sands S.A.
        • Eckert D.J.
        • et al.
        Acetazolamide improves loop gain but not the other physiological traits causing obstructive sleep apnoea.
        J Physiol. 2012; 590: 1199-1211
        • Fischer R.
        • Lang S.M.
        • Leitl M.
        • et al.
        Theophylline and acetazolamide reduce sleep-disordered breathing at high altitude.
        Eur Respir J. 2004; 23: 47-52
        • Nussbaumer-Ochsner Y.
        • Latshang T.D.
        • Ulrich S.
        • et al.
        Patients with obstructive sleep apnea syndrome benefit from acetazolamide during an altitude sojourn: a randomized, placebo-controlled, double-blind trial.
        Chest. 2012; 141: 131-138
        • Javaheri S.
        Acetazolamide improves central sleep apnea in heart failure: a double-blind, prospective study.
        Am J Respir Crit Care Med. 2006; 173: 234-237
        • Tojima H.
        • Kunitomo F.
        • Kimura H.
        • et al.
        Effects of acetazolamide in patients with the sleep apnoea syndrome.
        Thorax. 1988; 43: 113-119
        • Swenson E.R.
        • Leatham K.L.
        • Roach R.C.
        • et al.
        Renal carbonic anhydrase inhibition reduces high altitude sleep periodic breathing.
        Respir Physiol. 1991; 86: 333-343
        • Teppema L.J.
        • Boulet L.M.
        • Hackett H.K.
        • et al.
        Influence of methazolamide on the human control of breathing: a comparison to acetazolamide.
        Exp Physiol. 2020; 105: 293-301
        • Edwards B.A.
        • Connolly J.G.
        • Campana L.M.
        • et al.
        Acetazolamide attenuates the ventilatory response to arousal in patients with obstructive sleep apnea.
        Sleep. 2013; 36: 281-285
        • Eskandari D.
        • Zou D.
        • Karimi M.
        • et al.
        Zonisamide reduces obstructive sleep apnoea: a randomised placebo-controlled study.
        Eur Respir J. 2014; 44: 140-149
        • Gadde K.M.
        • Franciscy D.M.
        • Wagner 2nd, H.R.
        • et al.
        Zonisamide for weight loss in obese adults: a randomized controlled trial.
        JAMA. 2003; 289: 1820-1825
        • Parati G.
        • Revera M.
        • Giuliano A.
        • et al.
        Effects of acetazolamide on central blood pressure, peripheral blood pressure, and arterial distensibility at acute high altitude exposure.
        Eur Heart J. 2013; 34: 759-766
        • Eskandari D.
        • Zou D.
        • Grote L.
        • et al.
        Acetazolamide reduces blood pressure and sleep-disordered breathing in patients with hypertension and obstructive sleep apnea: a randomized controlled trial.
        J Clin Sleep Med. 2018; 14: 309-317
        • Hoff E.
        • Zou D.
        • Schiza S.
        • et al.
        Carbonic anhydrase, obstructive sleep apnea and hypertension: effects of intervention.
        J Sleep Res. 2020; 29e12956
        • Hedner J.
        • Stenlof K.
        • Zou D.
        • et al.
        A Randomized Controlled Clinical Trial Exploring Safety and Tolerability of Sulthiame in Sleep Apnea.
        Am J Respir Crit Care Med. Jun 15 2022; 205: 1461-1469https://doi.org/10.1164/rccm.202109-2043OC
        • Roy-Byrne P.P.
        The GABA-benzodiazepine receptor complex: structure, function, and role in anxiety.
        J Clin Psychiatry. 2005; 66: 14-20
        • Richter D.W.
        • Schmidt-Garcon P.
        • Pierrefiche O.
        • et al.
        Neurotransmitters and neuromodulators controlling the hypoxic respiratory response in anaesthetized cats.
        J Physiol. 1999; 514: 567-578
        • Eckert D.J.
        • Younes M.K.
        Arousal from sleep: implications for obstructive sleep apnea pathogenesis and treatment.
        J Appl Phys (1985). 2014; 116: 302-313
        • Carter S.G.
        • Carberry J.C.
        • Cho G.
        • et al.
        Effect of 1 month of zopiclone on obstructive sleep apnoea severity and symptoms: a randomised controlled trial.
        Eur Respir J. 2018; 52https://doi.org/10.1183/13993003.00149-2018
        • Carter S.G.
        • Carberry J.C.
        • Grunstein R.R.
        • et al.
        Randomized trial on the effects of high-dose zopiclone on OSA severity, upper airway Physiology, and Alertness.
        Chest. 2020; 158: 374-385
        • Messineo L.
        • Eckert D.J.
        • Lim R.
        • et al.
        Zolpidem increases sleep efficiency and the respiratory arousal threshold without changing sleep apnoea severity and pharyngeal muscle activity.
        J Physiol. 2020; 598: 4681-4692
        • Edwards B.A.
        • Sands S.A.
        • Owens R.L.
        • et al.
        The combination of supplemental oxygen and a hypnotic markedly improves obstructive sleep apnea in patients with a mild to moderate upper airway collapsibility.
        Sleep. 2016; 39: 1973-1983
        • Messineo L.
        • Carter S.G.
        • Taranto-Montemurro L.
        • et al.
        Addition of zolpidem to combination therapy with atomoxetine-oxybutynin increases sleep efficiency and the respiratory arousal threshold in obstructive sleep apnoea: a randomized trial.
        Respirology. 2021; 26: 878-886
        • Grace K.P.
        • Hughes S.W.
        • Horner R.L.
        Identification of a pharmacological target for genioglossus reactivation throughout sleep.
        Sleep. 2014; 37: 41-50
        • Taranto-Montemurro L.
        • Sands S.A.
        • Azarbarzin A.
        • et al.
        Effect of 4-aminopyridine on genioglossus muscle activity during sleep in healthy adults.
        Ann Am Thorac Soc. 2017; 14: 1177-1183
        • Wirth K.J.
        • Steinmeyer K.
        • Ruetten H.
        Sensitization of upper airway mechanoreceptors as a new pharmacologic principle to treat obstructive sleep apnea: investigations with AVE0118 in anesthetized pigs.
        Sleep. 2013; 36: 699-708
        • Gaisl T.
        • Turnbull C.D.
        • Weimann G.
        • et al.
        BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN).
        Eur Respir J. 2021; 58https://doi.org/10.1183/13993003.01937-2021
        • Carley D.W.
        • Paviovic S.
        • Janelidze M.
        • et al.
        Functional role for cannabinoids in respiratory stability during sleep.
        Sleep. 2002; 25: 391-398
        • Prasad B.
        • Radulovacki M.G.
        • Carley D.W.
        Proof of concept trial of dronabinol in obstructive sleep apnea.
        Front Psychiatry. 2013; 4: 1https://doi.org/10.3389/fpsyt.2013.00001
        • Carley D.W.
        • Prasad B.
        • Reid K.J.
        • et al.
        Pharmacotherapy of apnea by Cannabimimetic Enhancement, the PACE clinical trial: effects of dronabinol in obstructive sleep apnea.
        Sleep. 2018; 41https://doi.org/10.1093/sleep/zsx184
        • Ramar K.
        • Rosen I.M.
        • Kirsch D.B.
        • et al.
        Medical cannabis and the treatment of obstructive sleep apnea: an American Academy of sleep medicine position Statement.
        J Clin Sleep Med. 2018; 14: 679-681
        • Mulloy E.
        • McNicholas W.T.
        Theophylline in obstructive sleep apnea. A double-blind evaluation.
        Chest. 1992; 101: 753-757
        • Saletu B.
        • Oberndorfer S.
        • Anderer P.
        • et al.
        Efficiency of continuous positive airway pressure versus theophylline therapy in sleep apnea: comparative sleep laboratory studies on objective and subjective sleep and awakening quality.
        Neuropsychobiology. 1999; 39: 151-159
        • Hein H.
        • Behnke G.
        • Jorres R.A.
        • et al.
        The therapeutic effect of theophylline in mild obstructive sleep Apnea/Hypopnea syndrome: results of repeated measurements with portable recording devices at home.
        Eur J Med Res. 2000; 5: 391-399
        • Orth M.M.
        • Grootoonk S.
        • Duchna H.W.
        • et al.
        Short-term effects of oral theophylline in addition to CPAP in mild to moderate OSAS.
        Respir Med. 2005; 99: 471-476
        • Jokic R.
        • Klimaszewski A.
        • Mink J.
        • et al.
        Surface tension forces in sleep apnea: the role of a soft tissue lubricant: a randomized double-blind, placebo-controlled trial.
        Am J Respir Crit Care Med. 1998; 157: 1522-1525
        • Morrell M.J.
        • Arabi Y.
        • Zahn B.R.
        • et al.
        Effect of surfactant on pharyngeal mechanics in sleeping humans: implications for sleep apnoea.
        Eur Respir J. 2002; 20: 451-457
        • Kirkness J.P.
        • Madronio M.
        • Stavrinou R.
        • et al.
        Relationship between surface tension of upper airway lining liquid and upper airway collapsibility during sleep in obstructive sleep apnea hypopnea syndrome.
        J Appl Physiol (1985). 2003; 95: 1761-1766
        • Kiely J.L.
        • Nolan P.
        • McNicholas W.T.
        Intranasal corticosteroid therapy for obstructive sleep apnoea in patients with co-existing rhinitis.
        Thorax. 2004; 59: 50-55
        • Taranto-Montemurro L.
        • Sands S.
        • Azarbarzin A.
        • et al.
        Impact of cold and flu medication on obstructive sleep apnoea and its underlying traits: a pilot randomized controlled trial.
        Respirology. 2021; 26: 485-492
        • Popovic R.M.
        • White D.P.
        Upper airway muscle activity in normal women: influence of hormonal status.
        J Appl Physiol (1985). 1998; 84: 1055-1062
        • Martins F.O.
        • Conde S.V.
        Gender differences in the context of obstructive sleep apnea and metabolic diseases.
        Front Physiol. 2021; 12792633
        • Hedner J.
        • Grote L.
        • Zou D.
        Pharmacological treatment of sleep apnea: current situation and future strategies.
        Sleep Med Rev. 2008; 12: 33-47
        • Gasa M.
        • Tamisier R.
        • Launois S.H.
        • et al.
        Residual sleepiness in sleep apnea patients treated by continuous positive airway pressure.
        J Sleep Res. 2013; 22: 389-397
        • Javaheri S.
        • Javaheri S.
        Update on persistent excessive daytime sleepiness in OSA.
        Chest. 2020; 158: 776-786
        • Chapman J.L.
        • Vakulin A.
        • Hedner J.
        • et al.
        Modafinil/armodafinil in obstructive sleep apnoea: a systematic review and meta-analysis.
        Eur Respir J. 2016; 47: 1420-1428
        • Williams S.C.
        • Marshall N.S.
        • Kennerson M.
        • et al.
        Modafinil effects during acute continuous positive airway pressure withdrawal: a randomized crossover double-blind placebo-controlled trial.
        Am J Respir Crit Care Med. 2010; 181: 825-831
        • Roth T.
        • White D.
        • Schmidt-Nowara W.
        • et al.
        Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults.
        Clin Ther. 2006; 28: 689-706
        • Dauvilliers Y.
        • Bassetti C.
        • Lammers G.J.
        • et al.
        Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial.
        Lancet Neurol. 2013; 12: 1068-1075
        • Dauvilliers Y.
        • Verbraecken J.
        • Partinen M.
        • et al.
        Pitolisant for daytime sleepiness in patients with obstructive sleep apnea who Refuse continuous positive airway pressure treatment. A randomized trial.
        Am J Respir Crit Care Med. 2020; 201: 1135-1145
        • Pepin J.L.
        • Georgiev O.
        • Tiholov R.
        • et al.
        Pitolisant for residual excessive daytime sleepiness in OSA patients adhering to CPAP: a randomized trial.
        Chest. 2021; 159: 1598-1609
      1. (Available at:) (Accessed January 06 2022)
        • Thorpy M.J.
        • Shapiro C.
        • Mayer G.
        • et al.
        A randomized study of solriamfetol for excessive sleepiness in narcolepsy.
        Ann Neurol. 2019; 85: 359-370
        • Schweitzer P.K.
        • Rosenberg R.
        • Zammit G.K.
        • et al.
        Solriamfetol for excessive sleepiness in obstructive sleep apnea (TONES 3). A randomized controlled trial.
        Am J Respir Crit Care Med. 2019; 199: 1421-1431
        • Schweitzer P.K.
        • Mayer G.
        • Rosenberg R.
        • et al.
        Randomized controlled trial of solriamfetol for excessive daytime sleepiness in OSA: an analysis of subgroups adherent or Nonadherent to OSA treatment.
        Chest. 2021; 160: 307-318
        • Ronnebaum S.
        • Bron M.
        • Patel D.
        • et al.
        Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea.
        J Clin Sleep Med. 2021; 17: 2543-2555
        • Malhotra A.
        • Shapiro C.
        • Pepin J.L.
        • et al.
        Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea.
        Sleep. 2020; 43https://doi.org/10.1093/sleep/zsz220
        • Young T.
        • Palta M.
        • Dempsey J.
        • et al.
        The occurrence of sleep-disordered breathing among middle-aged adults.
        N Engl J Med. 1993; 328: 1230-1235
        • Young T.
        • Peppard P.E.
        • Gottlieb D.J.
        Epidemiology of obstructive sleep apnea: a population health perspective.
        Am J Respir Crit Care Med. 2002; 165: 1217-1239
        • Blackman A.
        • Foster G.D.
        • Zammit G.
        • et al.
        Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.
        Int J Obes (Lond). 2016; 40: 1310-1319
        • Drager L.F.
        • Brunoni A.R.
        • Jenner R.
        • et al.
        Effects of CPAP on body weight in patients with obstructive sleep apnoea: a meta-analysis of randomised trials.
        Thorax. 2015; 70: 258-264
        • Herculano S.
        • Grad G.F.
        • Drager L.F.
        • et al.
        Weight gain induced by continuous positive airway pressure in patients with obstructive sleep apnea is mediated by fluid accumulation: a randomized crossover controlled trial.
        Am J Respir Crit Care Med. 2021; 203: 134-136
        • Hedner J.
        • Grote L.
        • Bonsignore M.
        • et al.
        The European Sleep Apnoea Database (ESADA): report from 22 European sleep laboratories.
        Eur Respir J. 2011; 38: 635-642
        • Williams B.
        • Mancia G.
        • Spiering W.
        • et al.
        ESC/ESH Guidelines for the management of arterial hypertension.
        Eur Heart J. 2018; 39: 3021-3104
        • Garpestad E.
        • Basner R.C.
        • Ringler J.
        • et al.
        Phenylephrine-induced hypertension acutely decreases genioglossus EMG activity in awake humans.
        J Appl Physiol (1985). 1992; 72: 110-115
        • Mayer J.
        • Weichler U.
        • Herres-Mayer B.
        • et al.
        Influence of metoprolol and cilazapril on blood pressure and on sleep apnea activity.
        J Cardiovasc Pharmacol. 1990; 16: 952-961
        • Planes C.
        • Foucher A.
        • Leroy M.
        • et al.
        Effect of celiprolol treatment in hypertensive patients with sleep apnea.
        Sleep. 1999; 22: 507-513
        • Grote L.
        • Wutkewicz K.
        • Knaack L.
        • et al.
        Association between blood pressure reduction with antihypertensive treatment and sleep apnea activity.
        Am J Hypertens. 2000; 13: 1280-1287
        • Pepin J.L.
        • Tamisier R.
        • Barone-Rochette G.
        • et al.
        Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea.
        Am J Respir Crit Care Med. 2010; 182: 954-960
        • Kraiczi H.
        • Hedner J.
        • Peker Y.
        • et al.
        Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea.
        Am J Respir Crit Care Med. 2000; 161: 1423-1428
        • Khurshid K.
        • Yabes J.
        • Weiss P.M.
        • et al.
        Effect of antihypertensive medications on the severity of obstructive sleep apnea: a systematic review and meta-analysis.
        J Clin Sleep Med. 2016; 12: 1143-1151
        • Kasai T.
        • Bradley T.D.
        • Friedman O.
        • et al.
        Effect of intensified diuretic therapy on overnight rostral fluid shift and obstructive sleep apnoea in patients with uncontrolled hypertension.
        J Hypertens. 2014; 32: 673-680
        • Gaddam K.
        • Pimenta E.
        • Thomas S.J.
        • et al.
        Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report.
        J Hum Hypertens. 2010; 24: 532-537
        • Wu Z.H.
        • Yang X.P.
        • Niu X.
        • et al.
        The relationship between obstructive sleep apnea hypopnea syndrome and gastroesophageal reflux disease: a meta-analysis.
        Sleep Breath. 2019; 23: 389-397
        • Schuitenmaker J.M.
        • van Dijk M.
        • Oude Nijhuis R.A.B.
        • et al.
        Associations between sleep position and nocturnal gastroesophageal reflux: a study using Concurrent monitoring of sleep position and Esophageal pH and Impedance.
        Am J Gastroenterol. 2022; 117: 346-351
        • Friedman M.
        • Gurpinar B.
        • Lin H.C.
        • et al.
        Impact of treatment of gastroesophageal reflux on obstructive sleep apnea-hypopnea syndrome.
        Ann Otol Rhinol Laryngol. 2007; 116: 805-811
        • Ing A.J.
        • Ngu M.C.
        • Breslin A.B.
        Obstructive sleep apnea and gastroesophageal reflux.
        Am J Med. 2000; 108: 120S-125S
        • Senior B.A.
        • Khan M.
        • Schwimmer C.
        • et al.
        Gastroesophageal reflux and obstructive sleep apnea.
        Laryngoscope. 2001; 111: 2144-2146
        • Orr W.C.
        • Robert J.J.
        • Houck J.R.
        • et al.
        The effect of acid suppression on upper airway anatomy and obstruction in patients with sleep apnea and gastroesophageal reflux disease.
        J Clin Sleep Med. 2009; 5: 330-334